Radiotherapy for newly diagnosed oligometastatic prostate cancer
Mené en Suisse et au Royaume-Uni sur 2 061 patients atteints d'un cancer primitif métastatique de la prostate récemment diagnostiqué (âge médian : 68 ans), cet essai de phase III évalue, du point de vue de la survie globale, l'intérêt d'ajouter une radiothérapie à un traitement anti-androgénique en combinaison ou non avec le docétaxel
The standard of care for metastatic prostate cancer is systemic therapy in the form of androgen deprivation therapy with or without novel antiandrogens or chemotherapy. Administering local treatment to the primary tumour in the setting of metastatic prostate cancer has long been postulated to have a survival benefit on the basis of retrospective series. But such series can have selection bias in that patients undergoing local treatment can also have a low volume of metastatic disease (oligometastases), creating a major confounder in most analyses. To date randomised controlled trials investigating this subject have been sparse, and the value of local control in metastatic prostate cancer has been debated.
The Lancet , commentaire en libre accès, 2017